IMNM — Immunome Income Statement
0.000.00%
Last trade - 00:00- $1.79bn
- $1.52bn
- $9.04m
Annual income statement for Immunome, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 14 | 9.04 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 12.3 | 25.2 | 36.9 | 124 | 315 |
| Operating Profit | -12.3 | -25.2 | -36.9 | -110 | -306 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.8 | -24.7 | -36.9 | -107 | -293 |
| Net Income After Taxes | -17.8 | -24.7 | -36.9 | -107 | -293 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.8 | -24.7 | -36.9 | -107 | -293 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.8 | -24.7 | -37.5 | -107 | -293 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.67 | -2.14 | -3.09 | -1.31 | -2.4 |